In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
In yet another rejection of the company’s cancer drugs, the UK drugs watchdog, the National Institute for Health and Care Excellence (NICE), has issued new draft guidance for consultation that does not recommend National Health Service use of Swiss pharma major Roche’s Gazyvaro (obinutuzumab) for untreated chronic lymphocytic leukemia. 3 October 2014
US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma major Novartis related to reimbursement of Jakavi (ruxolitinib) in Europe. 2 October 2014
UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated a novel antibody-drug conjugate (ADC) targeting non-Hodgkin’s B-cell lymphoma and solid tumors. 2 October 2014
The US treatment market for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer will increase more than threefold in value, from $2.41 billion in 2013 to $7.95 billion by 2023, according to a new report from research and consulting firm GlobalData. 2 October 2014
French drugmaker Erytech and Italy's Recordati have reported positive Phase III results from its study of Graspa in acute lymphoblastic leukemia. 1 October 2014
German family-owned drug major Boehringer Ingelheim has presented new data at the annual congress of the European Society for Medical Oncology (ESMO) which came to a close in Madrid, Spain, yesterday. 1 October 2014
Data posters presented at this year’s European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, provide further evidence on the efficacy and quality of life profile of Halaven (eribulin) in the treatment of patients with locally advanced or metastatic breast cancer (MBC). 1 October 2014
Japanese drug major Astellas Pharma and Medivation has received extended approval for Xtandi (enzalutamide) from the US Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. 1 October 2014
An orphan drug could offer real hope to patients with rare thyroid cancer, Japanese drugmaker Eisai revealed at the European Society for Medical Oncology’s congress in Madrid. 30 September 2014
Seattle Genetics and Japan’s largest drugmaker Takeda Pharmaceutical have reported positive results from the Phase III trials of Adcetris (brentuximab vedotin) for consolidation in post-transplant Hodgkin’s lymphoma. 30 September 2014
US pharma major Pfizer and Japanese drugmaker Kyowa Hakko Kirin have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with mogamulizumab in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. 30 September 2014
Early results from pharma giant Merck & Co on the use of its Keytruda (pembrolizumab) in patients with advanced bladder cancer were presented at European Society for Medical Oncology’s congress in Madrid. 30 September 2014
Indian drugmaker Intas Pharmaceuticals says it has successfully launched the world’s first DoceAqualip with nanosomal docetaxel lipid suspension (NDLS) formula, in India. 30 September 2014
Oncology drug development company focused on antibody drug conjugates targeting major cancers, ADC Therapeutics, has expanded its team significantly as the company’s first antibody drug conjugates enter clinical development. 30 September 2014
US pharma major Bristol-Myers Squibb has announced multiple regulatory milestones for Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, in the USA and European Union. 30 September 2014
UK pharma major GlaxoSmithKline presented data at the European Society for Medical Oncology’s congress in Madrid showing 45% of patients treated with Tafinlar (dabrafenib) were still alive at two years. 29 September 2014
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies presented at the European Society for Medical Oncology (ESMO) 2014 Congress taking place in Madrid, Spain. 29 September 2014
Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences. Under the terms of the deal, Daiichi Sankyo has offered $15 per share. 29 September 2014